News & Media

Vancouver, BC (August 31, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that a poster presentation on the Company’s lead drug candidate Halneuron was accepted for presentation at the International Association for the Study of Pain (IASP)

Vancouver, BC (April 30, 2021) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for chronic pain, announced the publication of two clinical studies in a special issue of the Toxins Journal, Tetrodotoxin (TTX) as a Therapeutic Agent.

Vancouver, BC (March 30, 2018) ‐ WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing HalneuronTM (Tetrodotoxin or TTX) for pain, today announced the successful completion of the thorough electrocardiogram (“ECG”) study of Halneuron conducted in healthy volunteers.